NASDAQ:IFRX

InflaRx Stock Forecast, Price & News

$5.77

-0.13 (-2.20 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.72

Now: $5.77▼

$6.04

50-Day Range

$3.94

MA: $5.15▼

$6.31

52-Week Range

$2.52

Now: $5.77▼

$9.70

Volume180,321 shs

Average Volume457,169 shs

Market Capitalization$151.58 million

P/E RatioN/A

Dividend YieldN/A

Beta0.56

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

MarketRank^™

Overall MarketRank^™

1.26 out of 5 stars

Medical Sector

740th out of 1,928 stocks

Pharmaceutical Preparations Industry

373rd out of 774 stocks

3.3 Analyst's Opinion

Consensus Rating
InflaRx has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.17, InflaRx has a forecasted upside of 93.5% from its current price of $5.77.
Amount of Analyst Coverage
InflaRx has only been the subject of 3 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
InflaRx has received 203 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
InflaRx has received 223 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
InflaRx has received 52.35% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about InflaRx and other stocks. Vote “Outperform” if you believe IFRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
InflaRx does not currently pay a dividend.
Dividend Growth
InflaRx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InflaRx insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 13.71% of the stock of InflaRx is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for InflaRx are expected to grow in the coming year, from ($1.44) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of InflaRx is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InflaRx is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InflaRx has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IFRX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.inflarx.de

Phone49-36-4150-8180

Employees43

Debt

Debt-to-Equity RatioN/A

Current Ratio8.65

Quick Ratio8.65

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.62 per share

Price / Book1.25

Profitability

EPS (Most Recent Fiscal Year)($2.29)

Net Income$-59,650,000.00

Net MarginsN/A

Return on Equity-39.58%

Return on Assets-35.01%

Miscellaneous

Outstanding Shares26,270,000

Market Cap$151.58 million

Next Earnings Date5/5/2021 (Estimated)

OptionableNot Optionable

$5.77

-0.13 (-2.20 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

InflaRx (NASDAQ:IFRX) Frequently Asked Questions

How has InflaRx's stock been impacted by COVID-19 (Coronavirus)?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IFRX shares have increased by 78.6% and is now trading at $5.77.
View which stocks have been most impacted by COVID-19.

Is InflaRx a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" InflaRx stock.
View analyst ratings for InflaRx or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than InflaRx?

Wall Street analysts have given InflaRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but InflaRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as InflaRx's CEO?

1,428 employees have rated InflaRx CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among InflaRx's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for InflaRx.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.07.
View InflaRx's earnings history.

What price target have analysts set for IFRX?

7 equities research analysts have issued 12-month target prices for InflaRx's shares. Their forecasts range from $7.00 to $19.00. On average, they expect InflaRx's share price to reach $11.17 in the next year. This suggests a possible upside of 93.5% from the stock's current price.
View analysts' price targets for InflaRx or view Wall Street analyst' top-rated stocks.

Are investors shorting InflaRx?

InflaRx saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 663,100 shares, an increase of 34.7% from the December 15th total of 492,100 shares. Based on an average daily trading volume, of 344,500 shares, the days-to-cover ratio is currently 1.9 days. Currently, 3.4% of the company's stock are sold short.
View InflaRx's Short Interest.

Who are some of InflaRx's key competitors?

Some companies that are related to InflaRx include Akouos (AKUS), Spectrum Pharmaceuticals (SPPI), Relmada Therapeutics (RLMD), Flexion Therapeutics (FLXN), Clovis Oncology (CLVS), Molecular Templates (MTEM), Chimerix (CMRX), Neoleukin Therapeutics (NLTX), Atreca (BCEL), IDEAYA Biosciences (IDYA), Dynavax Technologies (DVAX), Five Prime Therapeutics (FPRX), Xenon Pharmaceuticals (XENE), ESSA Pharma (EPIX) and SIGA Technologies (SIGA).
View all of IFRX's competitors.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

Who are InflaRx's key executives?

InflaRx's management team includes the following people:

Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 48)
Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 50)
Dr. Thomas Taapken Ph.D., Chief Financial Officer (Age 55)
Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy
Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 38)
Ms. Katrin Reiher, Head of Quality Management (Age 38)
Mr. Jordan Zwick, Chief Strategy Officer
Dr. Korinna Pilz, Global Head of Clinical R&D

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $5.77.

How big of a company is InflaRx?

InflaRx has a market capitalization of $151.58 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. InflaRx employs 43 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is www.inflarx.de.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here